{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000659","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.254693+00:00","generated_at":"2026-06-15T20:52:11.187017+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunic reports phase 1b IMU-856 data: reduced villous height loss, improved symptoms, no safety issues","bullets":["Placebo group had 60.3 µm villous height reduction vs. 20.9 µm (80mg) and 22.5 µm (160mg) for IMU-856 (p=0.04) under gluten challenge.","On first gluten challenge day, placebo symptom increases (nausea 0.8, pain 0.8, diarrhea 0.8) vs. pooled IMU-856 (0.4, 0.5, 0.6) on 5-point scale.","Dose-dependent lessening of serum IL-2 release with IMU-856; citrulline levels increased in active arms while decreasing in placebo.","Vitamin B12 increased by 45.8 pmol/L (80mg) and 74.2 pmol/L (160mg) with IMU-856 vs. 31.0 pmol/L decrease with placebo.","No serious adverse events; two IMU-856 patients showed Q-Marsh histology improvement despite gluten challenge vs. none on placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000659","json":"https://secwatch.observer/filing/0001193805-23-000659.json","markdown":"https://secwatch.observer/filing/0001193805-23-000659.md","text":"https://secwatch.observer/filing/0001193805-23-000659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000659/0001193805-23-000659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000659/e618584_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:52:11.187017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}